Your Directors submit their report for the half-year ended 31 December 2009.

DIRECTORS

The names and details of the Company's directors in office during the half-year and until the date of this report are as below. Directors were in office for this entire period unless otherwise stated.

Melvyn Keith Ward
AO B.E.(Hons), M.Eng.Sc., F.I.E(Aust), F.T.S., F.A.I.M., I.V.A. (Chairman)

Dr Sam Aaron Hupert
M.B.B.S. (Deputy Chairman and Executive Director)

Dr Peter David Jonson
B.Comm(Hons), M.A.(Hons), PhD, F.A.I.C.D, F.A.A.S.S. (Non-Executive Director)

Anthony Barry Hall
B.Sc.(Hons), M.Sc. (Executive Director and Technology Director)

Peter Terence Kempen
FCA, FAICD (Non-Executive Director)

David Chambers
B.Sc. Grad Dip. Bus. (Managing Director and Chief Executive Officer)

REVIEW AND RESULTS OF OPERATIONS

Pro Medicus today reported a first half after tax profit of $1.236 million, a decrease of 48.9% on the December 2008 reported result. This was based on total revenue of $8.513m which increased by 64.6% compared with the comparable prior period. The increase in revenue reflects contributions from the acquisition of Visage Imaging which was not in the comparable period.

First-half profits are lower primarily due to the initial costs of integration of the two companies, further development and integration of next generation products, and joint establishment costs of a combined direct sales channel in the USA. Interest received is also down compared to the prior period as the company has expended some of its cash reserves for the acquisition of Visage Imaging and subsequent development costs. A currency gain last year ($0.7M) is also not being repeated this year.

This outcome is no surprise for the company which has planned and invested for a year that has seen a smoother than expected integration of Visage Imaging, the development and commercial release of it's next generation Visage 7 technology, coupled with complementary investments in the next generation of Pro Medicus RIS technology.

These investments are setting a strong base for future growth and have now been rewarded with large orders received in the closing stages of the half year. These are the already announced Lake Imaging deal, and a new deal with Southern Radiology Group. The company anticipates that a significant proportion of the revenue from these two deals will be realised prior to the 30th of June positioning the company well for a significantly stronger second half as previously forecast.

Our strategy has re-positioned the company and in so doing opened up a larger segment of the market in terms of up-selling existing clients and new client opportunities for both PACS and RIS in stand-alone or fully integrated mode. These opportunities are in both local and overseas markets.

Promedicus.net, the company's e-health offering, continued to perform well throughout the period.

The company has cash reserves, as at the end of December of over $3.3 million and continues to remain debt free.

The company feels that at the current stage of development and integration of the Visage acquisition it is prudent to place priority on conservation of its cash reserves. It has consequently announced it will defer a half year dividend and review its position again at year's end before deciding the quantum.

ROUNDING

The amounts contained in this report have been rounded to the nearest $1,000 (where rounding is applicable) under the option available to the company under ASIC Class Order 98/0100. The company is an entity to which Class Order applies.

AUDITORS' INDEPENDENCE DECLARATION

In accordance with section 307C of the Corporations Act 2001, we have obtained a declaration of independence from our auditors Ernst & Young, a copy of which is attached.

Signed in accordance with a resolution of the directors.

M K Ward
Chairman
Melbourne, 25 February 2010

Ernst & Young Building
8 Exhibition Street
Melbourne VIC 3000 Australia
GPO Box 67 Melbourne VIC 3001

Tel: +61 3 9288 8000
Fax: +61 3 8650 7777
www.ey.com/au

Auditor's Independence Declaration to the Directors of Pro Medicus Limited

In relation to our review of the financial report of Pro Medicus Limited for the half-year ended 31 December 2009, to the best of my knowledge and belief, there have been no contraventions of the auditor independence requirements of the *Corporations Act 2001* or any applicable code of professional conduct.

Ernst & Young

Ernst & Young

Painter

Stuart Painter
Partner
Melbourne
25 February 2010

STATEMENT OF COMPREHENSIVE INCOME		Consolidated	
FOR THE HALF-YEAR ENDED 31 DECEMBER 2009	**Notes**	**2009 $'000**	2008 $'000
Revenue		**8,433**	4,794
Finance Revenue		**80**	378
REVENUE		**8,513**	5,172
Cost of Sales		**(376)**	—
GROSS PROFIT		**8,137**	5,172
Other Income	3(a)	**—**	635
Accounting & Secretarial Fees		**(265)**	(152)
Advertising and Public Relations		**(478)**	(92)
Depreciation & Amortisation	3(b)	**(1,247)**	(361)
Insurance		**(162)**	(104)
Legal Costs		**(112)**	(32)
Operating Lease Expenditure – minimum lease payments		**(273)**	(85)
Other Expenses		**(461)**	(173)
Salaries and Employee Benefits Expense	3(b)	**(3,045)**	(1,467)
Travel and Accommodation		**(465)**	(149)
PROFIT BEFORE INCOME TAX		**1,629**	3,192
Income tax expense		**(393)**	(773)
NET PROFIT FOR THE PERIOD		**1,236**	2,419
Other Comprehensive income			
Foreign Currency translation		**(240)**	(5)
Other comprehensive income for the period		**(240)**	(5)
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD		**996**	2,414
- basic for net profit for half-year		**1.20¢**	2.42¢
- diluted for net profit for the half-year		**1.20¢**	2.43¢

STATEMENT OF FINANCIAL POSITION

AS AT 31 DECEMBER 2009	Notes	Consolidated Dec 2009 $'000	Consolidated Jun 2009 $'000
CURRENT ASSETS			
Cash and cash equivalents	6	**3,318**	5,561
Trade and other receivables		**4,581**	5,649
Income tax receivable		**448**	—
Inventories		**434**	495
Prepayments		**323**	247
TOTAL CURRENT ASSETS		**9,104**	11,952
NON-CURRENT ASSETS			
Deferred tax asset		**883**	590
Plant and equipment		**367**	477
Intangible assets	7	**10,654**	8,959
TOTAL NON-CURRENT ASSETS		**11,904**	10,026
TOTAL ASSETS		**21,008**	21,978
LIABILITIES			
CURRENT LIABILITIES			
Trade and other payables		**2,325**	2,721
Income tax payable		**—**	659
Provisions		**1,247**	1,261
TOTAL CURRENT LIABILITIES		**3,572**	4,641
NON-CURRENT LIABILITIES			
Deferred tax liabilities		**2,528**	1,409
Provisions		**55**	65
TOTAL NON-CURRENT LIABILITIES		**2,583**	1,474
TOTAL LIABILITIES		**6,155**	6,115
NET ASSETS		**14,853**	15,863
EQUITY			
Contributed Equity		**330**	330
Share Reserve		**35**	35
Foreign Currency Translation Reserve	2(b)	**(773)**	(533)
Retained Earnings		**15,261**	16,031
TOTAL EQUITY		**14,853**	15,863

pro medicus
OUR SUPPORT. YOUR SUCCESS.

STATEMENT OF CHANGES IN EQUITY

FOR THE HALF-YEAR ENDED 31 DECEMBER 2009

	Consolidated				
	Issued Capital	Share Reserve	Foreign Currency Translation Reserve	Retained Earnings	Total Equity
	$'000	$'000	$'000	$'000	$'000
At 1 July 2008	330	22	—	15,392	15,744
Profit for the period	—	—	—	2,419	2,419
Other comprehensive income	—	—	(5)	—	(5)
Total comprehensive income for the period	—	—	(5)	2,419	2,414
Transactions with owners in their capacity as owners					
Share based payment	—	5	—	—	5
Dividends	—	—	—	(3,259)	(3,259)
At 31 December 2008	330	27	(5)	14,551	14,903

	Issued Capital	Share Reserve	Foreign Currency Translation Reserve	Retained Earnings	Total Equity
	$'000	$'000	$'000	$'000	$'000
At 1 July 2009	330	35	(533)	16,031	15,863
Profit for the period	—	—	—	1,236	1,236
Other comprehensive income	—	—	(240)	—	(240)
Total comprehensive income for the period	—	—	(240)	1,236	996
Transactions with owners in their capacity as owners					
Share based payment	—	—	—	—	—
Dividends	—	—	—	(2,006)	(2,006)
At 31 December 2009	330	35	(773)	15,261	14,853

STATEMENT OF CASHFLOWS

HALF-YEAR ENDED 31 DECEMBER 2009	Notes	Consolidated 2009 $'000	2008 $'000
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipts from customers		**9,501**	6,852
Payments to suppliers and employees		**(6,022)**	(2,811)
Income tax paid		**(675)**	(1,803)
NET CASH FLOWS FROM OPERATING ACTIVITIES		**2,804**	2,238
CASH FLOWS USED IN INVESTING ACTIVITIES			
Capitalised Development Costs		**(2,703)**	(703)
Interest received		**80**	378
Purchase of property, plant and equipment		**(113)**	(18)
NET CASH FLOWS USED IN INVESTING ACTIVITIES		**(2,736)**	(343)
CASH FLOWS FROM FINANCING ACTIVITIES			
Payment of dividends on ordinary shares		**(2,006)**	(3,259)
NET CASH FLOWS FROM FINANCING ACTIVITIES		**(2,006)**	(3,259)
Net decrease in cash and cash equivalents		**(1,938)**	(1,364)
Net foreign exchange differences		**(305)**	—
Cash and cash equivalents at beginning of period		**5,561**	12,885
CASH AND CASH EQUIVALENTS AT END OF PERIOD	7	**3,318**	11,521

Notes to the Financial Statements

FOR THE HALF-YEAR ENDED 31 DECEMBER 2009

1. CORPORATE INFORMATION

The condensed half-year report of Pro Medicus Limited (the Company) for the half-year ended 31 December 2009 was authorised for issue in accordance with a resolution of directors on 25 February 2010.

Pro Medicus Limited is a company limited by shares incorporated and domiciled in Australia whose shares are publicly traded on the Australian stock exchange.

The nature of the operations and principal activities of the Company are described in note 2.

BASIS OF PREPARATION AND ACCOUNTING POLICIES

The condensed half-year financial report does not include all notes of the type normally included within the annual financial report and therefore cannot be expected to provide as full an understanding of the financial performance, financial position and financing and investing activities of the consolidated entity as the full financial report.

The condensed half-year financial report should be read in conjunction with the annual Financial Report of Pro Medicus Limited as at 30 June 2009.

It is also recommended that the half-year financial report be considered together with any public announcements made by Pro Medicus Limited during the half-year ended 31 December 2009 in accordance with the continuous disclosure obligations of the ASX listing rules.

(a) Basis of Preparation

The condensed half-year report is a general-purpose financial report, prepared in accordance with the requirements of the *Corporations Act 2001 and*, AASB 134 *Interim Financial Reporting.*

For the purpose of preparing the condensed half-year report, the half-year has been treated as a discrete reporting period.

(b) Significant accounting policies

Apart from the changes in accounting policy noted below, accounting policies and methods of computation are the same as those adopted in the most recent annual financial statements for the year ended 30 June 2009.

(c) Changes in accounting policy

The following amending standards have been adopted from 1 July 2009. Adoption of these standards did not have any effect on the financial position or performance of the Group.

- **AASB 101 Presentation of Financial Statements** - The revised Standard separates owner and non-owner changes in equity. The statement of changes in equity includes only details of transactions with owners, with non-owner changes in equity presented in a reconciliation of each component of equity and included in the new statement of comprehensive income. The statement of comprehensive income presents all items of recognised income and expense, either in one single statement, or in two linked statements. The Group has elected to present one statement.

- **AASB 8 Operating Segments** - AASB 8 replaced AASB 114 Segment Reporting upon its effective date. The Group concluded that the operating segments determined in accordance with AASB 8 are the same as the business segments previously identified under AASB 114. AASB 8 disclosures are shown in note 2, including the related revised comparative information.

- **AASB 3 Business Combinations (revised 2008) and AASB 127 Consolidated and Separate Financial Statements (revised 2008)** - AASB 3 (revised 2008) introduces significant changes in the accounting for business combinations occurring after this date. Changes affect the valuation of non-controlling interests (previously “minority interests”), the accounting for transaction costs, the initial recognition and subsequent measurement of contingent consideration and business combinations achieved in stages. These changes will impact the amount of goodwill recognised, the reported results in the period when an acquisition occurs and future reported results.
AASB 127 (revised 2008) requires that a change in the ownership interest of a subsidiary

(without a change in control) is to be accounted for as a transaction with owners in their capacity as owners. Therefore such transactions will no longer give rise to goodwill, nor will they give rise to a gain or loss in the statement of comprehensive income. Furthermore the revised Standard changes the accounting for losses incurred by a partially owned subsidiary as well as the loss of control of a subsidiary. The changes in AASB 3 (revised 2008) and AASB 127 (revised 2008) will affect future acquisitions, changes in, and loss of control of, subsidiaries and transactions with non-controlling interests. The change in accounting policy was applied prospectively and had no material impact on earnings per share.

- **AASB 123 Borrowing Costs** - The revised AASB 123 requires capitalisation of borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset. The Group's does not have any borrowing costs in the current year.

- **AASB 2008-7 Amendments to Australian Accounting Standards** - Cost of an Investment in a Subsidiary, Jointly Controlled Entity or Associate - The amendments delete the reference to the “cost method” making the distinction between pre and post acquisition profits no longer relevant. All dividends received are now recognised in profit or loss rather than having to be split between a reduction in the investment and profit and loss. However the receipt of such dividends requires an entity to consider whether there is an indicator of impairment of the investment in that subsidiary. The adoption of these amendments did not have any impact on the financial position or the performance of the Group.

- **AASB 2009-3 Amendments to Australian Accounting Standards** - Embedded Derivatives [AASB 139 and Interpretation 9] - These amendments to AASB Interpretation 9 require an entity to assess whether an embedded derivative must be separated from a host contract when the entity reclassifies a hybrid financial asset out of the fair value through profit or loss category. This assessment is to be made based on circumstances that existed on the later of the date the entity first became a party to the contract and the date of any contract amendments that significantly change the cash flows of the contract. AASB 139 now states that if an embedded derivative cannot be reliably measured, the entire hybrid instrument must remain classified as at fair value through profit or loss.

- **AASB Interpretation 16 Hedges of a Net Investment in a Foreign Operation** - The Interpretation is to be applied prospectively. AASB Interpretation 16 provides guidance on the accounting for a hedge of a net investment in a foreign operation. As such it provides guidance on identifying the foreign currency risks that qualify for hedge accounting in the hedge of a net investment, where within the group the hedging instruments can be held in the hedge of a net investment and how an entity should determine the amount of foreign currency gain or loss, relating to both the net investment and the hedging instrument, to be recycled on disposal of the net investment.

Notes to the Financial Statements

FOR THE HALF-YEAR ENDED 31 DECEMBER 2009

2. SEGMENT INFORMATION

The Group has identified its operating segments based on the internal reports that are reviewed and used by the executive management team (the chief operating decision makers) in assessing performance and in determining the allocation of resources.

The operating segments are identified by management based on country of origin. Discrete financial information is reported to the executive management team on at least a monthly basis.

The Group operates predominantly in one industry being, information technology within the health care industry and in three geographical areas being Australia, Europe and North America.

Types of products and services

The Group produces integrated software applications for the health care industry in addition the Group provides services in the form of installation and support.

Accounting policies

The accounting policies used by the Group in reporting segments internally is the same as those contained in note 1.

Operating Segments

	Australia		Europe		North America		Total Operations	
	2009	2008	**2009**	2008	**2009**	2008	**2009**	2008
Revenue	$'000	$'000	$'000	$'000	$'000	$'000	$'000	$'000
Sales to customers outside the company	**3,704**	4,203	**2,772**	-	**1,957**	591	**8,433**	4,794
Inter-segment Sales	**456**	-	**2,685**	-	**-**	-	**3,141**	-
Total segment revenue	**4,160**	4,203	**5,457**	-	**1,957**	591	**11,574**	4,794
Inter-segment elimination							**(3,141)**	-
Total consolidation revenue							**8,433**	4,794
Results								
Segment Result	**1,178**	2,848	**1,434**	-	**(1,063)**	(34)	**1,549**	2,814
Interest Revenue							**80**	378
Non segment expenses								
Income Tax Expense							**(428)**	(773)
Net Profit							**1,201**	2,419
Other segment information								
Capital expenditure	**2,146**	628	**639**	-	**32**	2,162	**2,816**	2,790
Depreciation and amortisation	**778**	114	**450**	**-**	**19**	247	**1,247**	361

	Dec 2009 $'000	Jun 2009 $'000	**Dec 2009 $'000**	Jun 2009 $'000	**Dec 2009 $'000**	Jun 2009 $'000	**Dec 2009 $'000**	Jun 2009 $'000
Assets								
Segment Assets	**13,471**	15,488	**4,627**	4,233	**2,560**	2,257	**20,658**	21,978
Total Assets							**20,658**	21,978
Liabilities								
Segment Liabilities	**2,196**	3,345	**2,798**	2,304	**566**	186	**5,560**	5,835
Total Liabilities							**5,560**	5,835

3. REVENUE AND EXPENSES

	Consolidated	
(a) Other Income		
Net Foreign Exchange Gains	**—**	635
	—	635
(b) Other Expenses		
Depreciation and Amortisation		
Property Improvements	**6**	6
Motor Vehicles	**28**	7
Office Equipment	**89**	12
Computer Equipment & Software	**99**	—
Furniture and Fittings	**4**	1
Research & Development Equipment	**11**	11
Amortisation on capitalised development costs	**734**	324
Intangible assets	**276**	—
Total Depreciation and Amortisation Expenses	**1,247**	361
Salaries and Employee Benefits Expense		
Wages & Salaries	**2,804**	1,240
Long service leave provision	**16**	17
Superannuation	**225**	210
	3,045	1,467
Net foreign exchange losses	**65**	—

	Consolidated	
4. DIVIDENDS PAID OR PROVIDED FOR ON ORDINARY SHARES	**2009 $'000**	2008 $'000
(a) Dividends proposed and recognised as a liability		
Franked dividend	—	—
(b) Dividends paid during the half-year		
Franked dividend	**2,006**	3,259
(c) Dividends proposed and not recognised as a liability		
Interim Fully Franked dividend	—	1,504
Dividends per share (cents per share)		
- Franked dividends paid per share (cents per share)	—	1.50¢
- interim dividend per share	—	1.50¢

5. EVENTS AFTER THE BALANCE SHEET DATE

There were no events after Balance Sheet date.

6. CASH AND CASH EQUIVALENTS

Reconciliation of Cash

For the purposes of the Cash Flow Statement, cash and cash equivalents comprise the following at 31 December:

	Dec 2009 $'000	Jun 2009 $'000
Cash at bank and in hand	**3,270**	5,514
Short-term deposits	**48**	47
	3,318	5,561

7. INTANGIBLE ASSETS

	Intellectual Property	Customer List	Consolidated Development Costs	Software Licenses	Total
	$'000	$'000	$'000	$'000	$'000
At 31 December 2009					
At 1 July 2009 net of accumulated amortisation and impairment	2,756	266	5,750	187	8,959
Additions - internal development	-	-	2,824	-	2,824
Amortisation charge for the period	(276)	(64)	(733)	(56)	(1,129)
At 31 December 2009 net of accumulated amortisation and impairment	2,480	202	7,841	131	10,654
At 31 December 2009					
Cost	3,006	343	10,157	278	13,784
Accumulated amortisation and impairment	(526)	(141)	(2,316)	(147)	(3,130)
Net carrying amount	2,480	202	7,841	131	10,654
Year ended 30 June 2009					
At 1 July 2008 net of accumulated amortisation and impairment	-	-	2,294	15	2,309
Additions - internal development	-		4,161	-	4,161
Additions	-	-	-	135	135
Acquisition of subsidiary	3,006	343	-	128	3,477
Disposals	-	-	-	-	-
Exchange differences	-	(37)	-	(14)	(51)
Amortisation charge for the year	(250)	(40)	(705)	(77)	(1,072)
At 30 June 2009 net of accumulated amortisation and impairment	2,756	266	5,750	187	8,959
At 30 June 2009					
Cost	3,006	986	7,333	75	11,400
Accumulated amortisation and impairment	(250)	(533)	(1,583)	(75)	(2,441)
Net carrying amount	2,756	453	5,750	-	8,959

8. BUSINESS COMBINATION

Acquisition of Visage Imaging Inc and Visage Imaging GmbH (Visage Imaging Group)
On 28 January 2009, Pro Medicus Limited acquired 100% of the voting shares of Visage Imaging Inc and Visage Imaging GmbH, both unlisted private company's based in United States and Germany respectively and specialising in information technology within the health care industry.

The total cost of the combination was $6,027,087 and comprised the payment of cash and costs directly attributable to the combination.

The fair value of the identifiable assets and liabilities of the Visage Imaging Group as at the date of acquisition have been adjusted from the provisional accounting as disclosed at 30 June 2009 as follows:

	Consolidated	
	Recognised on acquisition $000	**Carrying value $000**
Plant and equipment	**478**	**478**
Customer List	**343**	**343**
Software Licences	**128**	**128**
Deferred tax asset	**-**	**-**
Cash and cash equivalents	**1,182**	**1,182**
Trade receivables	**2,841**	**2,841**
Intellectual Property – Software	**3,006**	**-**
Inventories	**769**	**769**
	8,747	**8.747**
Trade payables	**(17)**	**(17)**
Employee Entitlements	**(471)**	**(471)**
Deferred Revenue	**(482)**	**(482)**
Deferred tax liabilities*	**(281)**	**-**
Other payables	**(1,068)**	**(1,068)**
	(2,319)	**(2,038)**
Fair value of identifiable net assets	**6,428**	
Gain on acquisition of subsidiaries*	**(401)**	
	6,027	
Cost of the combination:		
Cash paid	**4,004**	
Direct costs relating to the acquisition	**1,160**	
Acquisition costs remaining to be paid at 30 June	**863**	
Total cost of the combination	**6,027**	
The cash outflow on acquisition is as follows:		
Net cash acquired with the subsidiary	**1,182**	
Cash paid	**(5,164)**	
Net consolidated cash outflow	**(3,982)**	

The only adjustments made to the 30 June 2009 provisional accounting were to increase deferred tax liabilities by $281,000 to $281,000 and reduce the gain on acquisition of subsidiaries by $281,000 to $401,000. These adjustments have been reflected in the 30 June 2009 comparative numbers.

Directors' Declaration

In accordance with a resolution of the directors of Pro Medicus Limited, I state that:

In the opinion of the directors:

(a) The Financial Statements and notes of the consolidated entity are in accordance with the *Corporations Act 2001*, including:

  (i) giving a true and fair view of the consolidated entity financial position as at 31 December 2009 and of its performance for the half-year ended on that date; and

  (ii) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the Corporations Regulations 2001; and

(b) There are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

On behalf of the Board

M K Ward

Chairman

Melbourne, 25 February 2010

Ernst & Young Building
8 Exhibition Street
Melbourne VIC 3000 Australia
GPO Box 67 Melbourne VIC 3001

Tel: +61 3 9288 8000
Fax: +61 3 8650 7777
www.ey.com/au

To the members of Pro Medicus Limited

Report on the Half-Year Financial Report

We have reviewed the accompanying half-year financial report of Pro Medicus Limited, which comprises the statement of financial position as at 31 December 2009, and the statement of comprehensive income, statement of changes in equity and statement of cash flows for the half-year ended on that date, other selected explanatory notes and the directors' declaration of the consolidated entity comprising the company and the entities it controlled at the half-year end or from time to time during the half-year.

Directors' Responsibility for the Half-Year Financial Report

The directors of the company are responsible for the preparation and fair presentation of the half-year financial report in accordance with Australian Accounting Standards (including the Australian Accounting Interpretations) and the *Corporations Act 2001*. This responsibility includes establishing and maintaining internal controls relevant to the preparation and fair presentation of the half-year financial report that is free from material misstatement, whether due to fraud or error; selecting and applying appropriate accounting policies; and making accounting estimates that are reasonable in the circumstances.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of Interim and Other Financial Reports Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the consolidated entity's financial position as at 31 December 2009 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001* . As the auditor of Pro Medicus Limited and the entities it controlled during the half-year, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*. We have given to the directors of the company a written Auditor's Independence Declaration, a copy of which follows the Directors' Report.

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Pro Medicus Limited is not in accordance with the *Corporations Act 2001*, including:

i) giving a true and fair view of the consolidated entity's financial position as at 31 December 2009 and of its performance for the half-year ended on that date; and

ii) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Ernst & Young

Ernst & Young

Stuart Painter
Partner
Melbourne
25 February 2010